TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants
Brief Summary: The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age.

This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.


Options:
A: Inclusion Criteria:

* premature neonates \< 33 weeks gestational age

Exclusion Criteria:

* major congenital anomalies
* prior use of cytokines
B: Inclusion Criteria (preterm):

* birth weight 500-1,250 grams, gestational age ≤32 weeks
* hematocrit ≤55%
* ≤48 hours of age
* expected to survive greater than 72 hours
* consent signed by parent or guardian

Inclusion Criteria (term):

Former term born infants will be eligible if they have not experienced any episodes of hypoxia, hypoglycemia, hyperbilirubinemia, prenatal drug exposure, or sepsis.

Exclusion Criteria (former preterms):

* hemorrhagic or hemolytic disease
* major congenital anomalies (such as trisomy 13, 18 or 21)
* major neurologic abnormality such as hydrocephalus or meningomyelocele
* complex congenital heart disease
* receiving Epo or are enrolled in an Epo study
* evidence of disseminated intravascular coagulation
* clinical seizures are present
* congenital thrombotic disease is suspected
* systolic blood pressures \>100 mm Hg (while not on pressor support) Infants with minor anomalies such as clinodactyly, single umbilical vessel or patent ductus are not excluded

Exclusion criteria (term):

hypoxia, hypoglycemia, hyperbilirubinemia, prenatal drug exposure, or sepsis
C: Inclusion Criteria:

* Infants born between 26 0/7 and 31 6/7 gestational weeks
* Postnatal age less than 3 hours
* Informed parental consent (preferably obtained before birth)

Exclusion Criteria:

* Genetically defined syndrome
* Severe congenital malformation adversely affecting life expectancy
* Severe congenital malformation adversely affecting neurodevelopment
* A priory palliative care
* Intracranial haemorrhage grade 3 or more detected before dose 3 of Erythropoietin
D: Inclusion Criteria:

* 500-1250 grams birth weight
* less than or equal to 32 weeks gestation
* less than 2 days of age

Exclusion Criteria:

* severe hemorrhagic disease
* severe hemolytic disease
* DIC
* seizures
* hypertension
* thromboses
* receiving erythropoietin

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phone Calls to Promote Adherence With Inhaled Corticosteroids
Brief Summary: Inhaled corticosteroids (ICS) are often prescribed as a treatment for asthma. However, many individuals who take these medications do not adhere to their prescribed treatment regimen. The purpose of this study is to evaluate the effectiveness of a telephone-based program at improving medication adherence among individuals with asthma.


Options:
A: Inclusion Criteria:

1) female aged \>18 years, 2) completed primary and adjuvant treatment for breast cancer (patients on hormone treatment such as Tamoxifen will be eligible). Women on chemotherapy will become eligible 6 months after treatment completion, and will remain eligible up to 10 years posttreatment; 3) \<10 years since treatment completion, 4) able to read and speak English, 5) provide consent for medical chart review to extract disease and treatment variables, 6) able to walk unassisted, are 7) sedentary defined as: currently not meeting ACSM/CDC criteria (Pate et al, 1995) for moderate-intensity activity (\>30 mins. per day on \>5 days per week) or vigorous-intensity activity (\>20 mins. on \>3 days per week), and 8) have access to a telephone. -

Exclusion Criteria:

-
B: Inclusion Criteria:

* uncontrolled hypertension
* systolic blood pressure \> 140
* access to a telephone or internet

Exclusion Criteria:

* angina
* cognitive defects, dementia
* end stage renal disease
* living in nursing or boarding homes
* pregnant
* unable to sign informed consent
* unable to use a scale, sphygmomanometer, pedometer
C: Inclusion Criteria:

* Aged 14 - 24 years of age
* Proficient English
* Patients must be deemed to have an emotional/mental health concern by their GP or be screened to have at least a mild mental health problem (a score of 16 or above) on the K10 Symptom Scale

Exclusion Criteria:

* Severe psychiatric or medical condition that prevents the person from complying with either the requirements of informed consent or the study protocol.
* Young people referred to a mental health specialist by their GP will be excluded only if they obtain a specialist appointment during the mobiletype study period (2 - 4 weeks).
D: Inclusion Criteria:

* Received treatment for asthma in the year prior to study entry
* Received at least one respiratory medication at a Kaiser Permanente Northwest (KPNW) or Kaiser Permanente Hawaii (KPH) outpatient pharmacy in the year prior to study entry
* Continuous Kaiser Permanente membership from the year prior to study entry through study entry
* Willing to participate in the study

Exclusion Criteria:

* Excluded from primary analyses if fewer than three months of follow-up

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phone Calls to Promote Adherence With Inhaled Corticosteroids
Brief Summary: Inhaled corticosteroids (ICS) are often prescribed as a treatment for asthma. However, many individuals who take these medications do not adhere to their prescribed treatment regimen. The purpose of this study is to evaluate the effectiveness of a telephone-based program at improving medication adherence among individuals with asthma.


Options:
A: Inclusion Criteria:

* Doctor diagnosed asthma.
* On at least BTS stage 2, which means they will be on regular inhaled steroids.
* No change in regular asthma treatment in the last 1 month (on regular inhaled steroids, no change in steroid dose for

  1 month, no change in add on therapy in the last month).
* ACQ (Asthma Control Questionnaire) score more than or equal to 1.5.
* Can speak and understand English.

Exclusion Criteria:

* BTS stage 5 asthma (complex issues, too unstable).
* Recent changes to asthma treatment within the last month. (see above)
* ACQ (Asthma Control Questionnaire) score \< 1.5.
* Another chronic health condition (eg diabetes, congenital heart disease, cystic fibrosis).
* Can't speak or understand English.
B: Inclusion Criteria:

* Received treatment for asthma in the year prior to study entry
* Received at least one respiratory medication at a Kaiser Permanente Northwest (KPNW) or Kaiser Permanente Hawaii (KPH) outpatient pharmacy in the year prior to study entry
* Continuous Kaiser Permanente membership from the year prior to study entry through study entry
* Willing to participate in the study

Exclusion Criteria:

* Excluded from primary analyses if fewer than three months of follow-up
C: Inclusion Criteria:

* patient has been diagnosed with asthma for at least 6 months
* patient can be managed appropriately on study medications as determined by the attending physician

Exclusion Criteria:

* patient shows evidence of neurological or significant cognitive impairment
D: Inclusion Criteria (patient-level):

* Age 5-56 years
* Physician diagnosis of asthma
* Continuous HMO enrollment with prescription drug rider
* Electronic prescription of an inhaled corticosteroid

Exclusion Criteria (patient-level):

* Diagnosis of chronic obstructive pulmonary disease
* Diagnosis of congestive heart failure

Inclusion Criteria (practice-level):

* Primary care practice (i.e., pediatrics, family practice, or internal medicine) within the health system. A practice is defined as a group of physicians who by virtue of speciality or geography care for a relatively contained population of patients and who cross-cover the care of these patients.

Exclusion Criteria (practice-level):

* None

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Stroke Warning Information and Faster Treatment Study (SWIFT)
Brief Summary: The purposes of this study are to determine the effectiveness of an interactive stroke educational program compared to standard educational materials and usual care, to increase stroke knowledge, and to improve emergency room arrival times upon onset of stroke symptoms.


Options:
A: Inclusion Criteria:

* The study will include all women delivering at one of the maternity units involved in for the duration of the study.

Exclusion Criteria:

* Women delivering in the "washout" period in each unit.
B: Inclusion Criteria:

* a diagnosis of ischemic heart disease, confirmed by their physician or medical record
* lived independently (i.e., not in an institutional setting).

Exclusion Criteria:

* complicating serious co-morbidity such as a psychiatric illness or untreated malignancy
* neurological disorder with impaired cognition
* inability to read or understand English.
* major uncorrected hearing loss
C: Inclusion Criteria:

* Diagnosed with cerebral infarction/TIA hospitalized at New York Presbyterian Hospital (Milstein Hospital and Allen Pavilion)
* 18 year-old and older at onset of the stroke
* Self-identified as of White, Black or Hispanic race-ethnicity
* Living in a household with a telephone

Exclusion Criteria:

* Patients unable to give informed consent
* Discharged to nursing home or requiring 24 hour care.
* A Modified Rankin score \> 4 at baseline
* Severe aphasia or severe cognitive impairment limiting comprehension
* Pre-stroke dementia history
* Patients with end stage cancer, or other medical conditions resulting in mortality \</= 1 year
D: Inclusion Criteria:

* 4th-6th grade children and their parents in selected elementary public schools in the same geographical region/community with similar socioeconomic status (SES) and Ethnic composition.

Exclusion Criteria:

* School located in Harlem, New York.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomised Controlled Trial to Evaluate the Preventive Effect on Mortality and Serious Morbidity/ Hospitalisations of Daily Vitamin D Supplements in Small for Gestational Age Term Infants
Brief Summary: The purpose of this study is to determine whether a weekly supplement of vitamin D to low birth weight term infants will reduce their mortality and hospital admissions and improve their immunity.


Options:
A: Inclusion Criteria:

1. Healthy children by parental report
2. Have reached their 1st birthday but not past their 6th birthday
3. Present to a TARGet Kids! practice for routine primary healthcare prior to viral season (September through November)
4. Parents provide informed consent to participate.

Exclusion Criteria:

1. Children with gestational age \< 32 weeks
2. Children with chronic illness (except for asthma) on parental report which is known to interfere with vitamin D metabolism and increase the risk of respiratory infection
3. Children with a sibling participating in the study to reduce clustering effects.
B: Inclusion Criteria:

* Preterm infants with gestational age 28-33 weeks

Exclusion Criteria:

* Necrotizing enterocolitis
* Bowel perforation
* Chromosomal anomalies
* Inborn errors of metabolism
* Major congenital anomalies
C: Inclusion Criteria:

* Born at term, as determined from last menstrual period
* Weighing \< 2.5 kg
* Resident within 12 km of the hospital and expected to continue living in the area for the following 6 months
* With no severe congenital abnormalities
* No morbidity severe enough to be expected to result in death before 7 days due to severe respiratory distress, shock, pulmonary sepsis, etc.
* Parental informed consent
D: Inclusion Criteria: Singleton, live born infants born to HIV-infected women Exclusion Criteria: Infants with multiple congenital abnormalities

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.


Options:
A: Inclusion Criteria:

* General medical practices in NHS Fife and NHS Tayside with a compatible clinical IT system and agreeing to participate.
* Practices that agree to have relevant medication related data to be automatically extracted from their electronic clinical information systems from 1/10/10 to 30/9/13 (ie 12 months before first practice starts till 12 months after last practice starts).

Exclusion Criteria:

* Practices that use General Practice Administration System for Scotland (GPASS) or Egton Medicine Information System (EMIS) on the date of randomisation, since data extraction for the informatics requires Vision practice IT system.
B: Inclusion Criteria:

* children aged 7 days to 3 years old
* fever without source ≥ 100.4°F (≥ 38.0°C)

Exclusion Criteria:

* antibiotics received in the previous 48 hours
* underlying congenital or acquired immunodeficiency syndrome
* fever for more than 7 days at presentation
C: Inclusion Criteria:

* suspected lower respiratory tract infection
* must be able to give consent

Exclusion Criteria:

* age under 18 years
* not able to give consent
* admitted not primarily because of the respiratory tract infection
* hospital acquired infections
D: Inclusion Criteria:

* All patients prescribed vancomycin, piperacillin-tazobactam, or levofloxacin during the time period of the study.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Ecological Momentary Intervention of Diet Via Mobile Technology
Brief Summary: This is a NCI funded study which will develop and evaluate a cell phone application (mDIET) that can be used as an assessment and intervention tool to improve dietary behaviors and thus reduce weight in overweight and moderately obese (BMI 25-34.9) men and women ages 25-55.


Options:
A: Inclusion Criteria:

* mother of infant aged 2-12 months
* sedentary
* healthy, able to do moderate intensity physical activity
* BMI = 18.5-40
* not planning to become pregnant in next year
* woman aged 18-45
* able speak and read English

Exclusion Criteria:

* pregnant
* planning to leave Oahu, Hawaii in the next year (permanently move away)
* a diagnosis of cancer, coronary heart disease (including atrial fibrillation), insulin-dependent diabetes mellitus (IDDM), and other atherosclerotic cardiovascular diseases (e.g., stroke),
B: Inclusion Criteria:

* Families with healthy adults and children

Exclusion Criteria:

* Various
C: Inclusion Criteria:

* Participants will be included if they:

  * Are age 25-55
  * Are overweight or moderately obese
  * Are with a BMI between 25.0-34.9 (as defined by the NIH report on Obesity (NIH 1998)
  * Are able to read (completion of at least the 6th grade) and speak English
  * Provide consent
  * Do not intend to become pregnant or move out of the county for the duration of the intervention (16 weeks).
* Participants will also be required to have a cell phone that is capable of supporting the mDIET application.
* Participants may be otherwise healthy or have one or more risk factors for CVD, including uncomplicated Type 2 diabetes but will not be enrolled if they have diagnosed CVD.

Exclusion Criteria:

Participants will be excluded from the study if they have any of the following conditions:

* An eating disorder
* Are currently pregnant
* Have a strict dietary regimen prescribed by their doctor that will not allow them to comply with intervention guidelines related to dietary changes.
D: Inclusion Criteria:

* Body mass index (BMI) between 25.0 and 39.9 kg/m2

Exclusion Criteria:

* Reports losing more than 5% of current body weight in the 6 months before study entry
* Participated in a research project involving weight loss or physical activity in the 6 months before study entry
* Pregnant during the 6 months before study entry, currently breastfeeding, or planning to become pregnant in the 18 months after study entry
* Current treatment for any medical condition that could affect body weight (e.g., diabetes mellitus, cancer)
* History of heart attack or heart surgery, including bypass or angioplasty
* Currently taking medication that would affect heart rate or blood pressure responses to exercise (e.g., beta blockers)
* Currently taking medication that could affect metabolism or change body weight (e.g., synthroid)
* Currently being treated for psychological issues or has taken psychotropic medications in the 6 months before study entry

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients
Brief Summary: The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation during an IVF cycle. Our hypothesis is that the GnRH antagonist protocol reduces the occurrence and severity of OHSS compared to the GnRH agonist protocol.


Options:
A: Inclusion Criteria:

* All patients referred for infertility receiving their first IVF or IVF+ICSI treatment

Exclusion Criteria:

* Previous IVF or IVF+ICSI-treatment
* Uterine anomalies
* It is necessary to perform direct sperm aspiration from husband's/partner's testicles
* Allergy to one of the intervention products
* Patient is 40 years or above
B: Inclusion Criteria:

* Clinical diagnosis of PCOS (presence of oligo-ovulation/anovulation and polycystic ovaries)

Exclusion Criteria:

* Normal responders
* Poor responders
C: Inclusion Criteria:

* Puregon® (recFSH)/Orgalutran® group:

  * Women with a pregnancy of \>= 16 weeks after Puregon® /Orgalutran® treatment for IVF or ICSI and ET of fresh embryos. Treatment is defined as having had at least one injection of Orgalutran®.
  * Women between 18 and 39 years of age (inclusive) at the day of hCG.
  * Women who are able and willing to sign informed consent.

Controls

* Infants (gestational age \>=16 weeks) of women pregnant after COH using a GnRH agonist in a long protocol for IVF or ICSI and ET of fresh embryos.
* Infants of women between 18 and 39 years of age (inclusive) at the day of hCG.
* The most recent 1000 infants delivered prior to January 1, 2001.

Exclusion Criteria:

* None
D: Inclusion Criteria:

* age \< 39
* follicle-stimulating hormone (FSH) \< 12
* gonadotropin dose 100-300IU

Exclusion Criteria:

* endometriosis
* known endocrine disorder
* blood analyzed in another laboratory

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dressing: Comparison of 3-day and 7-day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-related Infection in ICU
Brief Summary: The purpose of this study is to determine whether a catheter dressing every 7th day is not inferior to a catheter dressing every 3 days and if Chlorhexidine impregnated sponges are effective in preventing catheter-related infections in ICUs.


Options:
A: Inclusion Criteria:

* patients older than 18 years
* with at least a central venous catheter or an arterial catheter
* whatever the first or subsequent CVC in a same patient
* in any site of insertion (sub-clavian, jugular or femoral)
* whatever le CVC is tunnelled or not
* CVC inserted in the study ICU or immediately before by the intensisvist in the emergency unit or in the operative room,
* CVC inserted under maximal barrier precautions

Exclusion Criteria:

* pulmonary artery catheter, haemodialysis/haemodiafiltration CVCs
* known allergy to chlorhexidine
* CVC not inserted under maximal barrier precautions
* Expected duration of CVC for less than 48 hours
* CVC inserted under emergency conditions
B: Inclusion Criteria:

* ≥ 18 year-old
* Expected duration of ICU stay ≥ 48 hours
* Patient requiring the insertion of at least one arterial catheter and/or central venous catheter and/or catheter for hemodialysis.

Exclusion Criteria:

* Patient with history of allergy to any of the antiseptic agent studied
* Expected survival \< 48 hours
* Catheter inserted outside the ICU or in emergency without respect of preventive measures.
* Use of antimicrobial impregnated catheters or antiseptic impregnated dressings.
* Pregnant woman or breast-feeding mother
C: Inclusion Criteria:

* Patients \>18 years
* Medical indication for CVC with a planned duration of minimum 5 days
* Patient´s (or relative´s if applicable) written informed consent

Exclusion Criteria:

* Known sensitisation against the proposed antiseptics
* Tunneled or implanted CVCs (e.g. Hickman Catheter)
* Administration of antimicrobial drugs for therapy (not prophylaxis) less than one week prior to catheterization
* Pre-existing bloodstream infection (i.e., fever and/or other signs of infection)
* Positive blood culture
* Terminal patients with limited therapy options
* Patients with burns
* Patients participating in a clinical trial on other antiseptics within a period of four weeks prior to inclusion date
* Patients with missing written consent
D: Inclusion Criteria:

* Patients over 18 yeras of age
* Requiring an internal jugular or sub-clavian central venous catheter for their care during at least 72 h
* Informed consent signed up

Exclusion Criteria:

* Bacteriemic infection not under control
* extensive cutaneous infection
* Women with childbearing potential

Answer: A